MREO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Mereo BioPharma Group PLC (MREO) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is facing significant negative catalysts, including failed clinical trials, multiple class action lawsuits, and deteriorating financial performance. Additionally, there are no strong technical, options, or proprietary trading signals to suggest a buying opportunity.
The technical indicators are bearish overall. The MACD is positive but contracting, RSI is neutral at 34.772, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 0.403, with key support at 0.363 and resistance at 0.442. Pre-market price is down 2.15%, indicating weak sentiment.
NULL identified. Bone mineral density improvements in clinical trials may provide a potential path to market, but this is highly speculative and uncertain.
Failed Phase 3 clinical trials for setrusumab, multiple class action lawsuits alleging securities fraud, significant price target downgrades by analysts, and a lack of insider or hedge fund activity. Financial performance is also weak, with a significant drop in net income and EPS.
In 2025/Q3, the company's revenue remained at 0 with no YoY growth. Net income dropped by 53.18% YoY to -$7,024,000, and EPS fell by 50% YoY to -0.01. Gross margin increased slightly to 73.4%, but this does not offset the overall poor financial performance.
Analysts have significantly downgraded the stock following failed clinical trials. Price targets have been slashed (e.g., Cantor Fitzgerald reduced from $6 to $3, BTIG from $6 to $1, Jefferies from $7 to $0.50). Ratings have been downgraded to Hold or Market Perform, reflecting low confidence in the company's future prospects.
